ClinicalTrials.Veeva

Menu

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7)

Celgene logo

Celgene

Status and phase

Active, not recruiting
Phase 2
Phase 1

Conditions

Multiple Myeloma

Treatments

Drug: BMS-986405
Biological: BB2121
Drug: CC-220

Study type

Interventional

Funder types

Industry

Identifiers

NCT04855136
2020-003248-10 (EudraCT Number)
BB2121-MM-007

Details and patient eligibility

About

This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to determine the safety, tolerability, efficacy, PK of bb2121 in combination with other therapies in adult subjects with R/RMM.

The following combinations will be

  • Arm A will test bb2121 in combination with CC-220 (± low-dose dexamethasone)
  • Arm B will test bb2121 in combination with BMS-986405 (JSMD194)

Combination agents being tested may be administered before, concurrently with and/or following (ie, maintenance) bb2121 infusion.

The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose expansion may occur in one or more arms.

Enrollment

312 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants must satisfy the following criteria to be enrolled in the study:

  • Participant has documented diagnosis of MM and measurable disease, defined as:

    1. M-protein (serum protein electrophoresis [sPEP ≥ 0.5 g/dL] or urine protein electrophoresis [uPEP]): uPEP ≥ 200 mg/24 hours and/or
    2. Light chain MM without measurable disease in the serum or urine: Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio
  • Participant has received:

    1. at least 3 prior MM regimens for Arm A Cohort 1 and Arm B
    2. at least 1 but no greater than 3 prior MM regimens for Arm A Cohort 2
  • Arm A Cohort 1 and Arm B: Participant has received prior treatment with an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody-containing regimen for at least 2 consecutive cycles.

  • Arm A Cohort 2: Participant has received prior treatment with an immunomodulatory agent for at least 2 consecutive cycles.

  • Evidence of PD during or within 6 months (measured from the last dose of any drug within the regimen) of completing treatment with the last antimyeloma regimen before study entry.

  • Participant achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen.

  • Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion criteria

The presence of any of the following will exclude a participant from enrollment:

  • Participant has non-secretory MM or has history of or active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or amyloidosis.

  • Participant has any of the following laboratory abnormalities:

    1. ANC and Platelets count as reported below
    2. Hemoglobin < 8 g/dL (< 4.9 mmol/L) (transfusion is not permitted within 21 days of screening)
    3. Creatinine clearance (CrCl) as reported below
    4. Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L)
    5. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 ×upper limit of normal (ULN)
    6. Serum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for participants with documented Gilbert's syndrome
    7. International normalized ratio (INR) or activated partial thromboplastin time (aPTT) 1.5 × ULN, or history of Grade ≥ 2 hemorrhage within 30 days, or participant requires ongoing treatment with chronic, therapeutic dosing of anticoagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors)
  • Participant has inadequate pulmonary function defined as oxygen saturation (SaO2) < 92% on room air.

  • Participant has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) 50% of predicted normal.

  • Prior exposure to CC-220 (± low-dose dexamethasone) as part of their most recent antimyeloma treatment regimen (Arm A).

  • Prior exposure to BMS-986405 (JSMD194) (Arm B).

  • Previous history of an allogeneic hematopoietic stem cell transplantation, treatment with any gene therapy-based therapeutic for cancer, investigational cellular therapy for cancer or BCMA targeted therapy.

  • Treatment Arm A Cohort 1 and Arm B: participant has received autologous stem cell transplantation (ASCT) within 12 weeks prior to leukapheresis.

  • Treatment Arm A Cohort 2: participant has received autologous stem cell transplantation (ASCT) within 12 months prior to leukapheresis.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

312 participants in 2 patient groups

Arm A- bb2121 in combination with CC-220 (± low-dose dexamethasone)
Experimental group
Description:
bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agent will be administered at different doses and/ or schedules, depending on dose limiting toxicity (DLT) evaluation.
Treatment:
Drug: CC-220
Biological: BB2121
Arm B- bb2121 in combination with BMS-986405 (JSMD194)
Experimental group
Description:
bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agent will be administered during Month 1 starting from the day of bb2121 infusion Enrollment is closed for this Arm
Treatment:
Biological: BB2121
Drug: BMS-986405

Trial contacts and locations

17

Loading...

Central trial contact

BMS Study Connect Contact Center www.BMSStudyConnect.com; First line of the email MUST contain NCT # and Site #.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems